Day 2: Wednesday, 12/6/2017

GENERAL SESSION 1 – Hall 3

Moderator: Sibylle Loibl, MD, PhD

German Breast Group=

Neu­Isenburg,  GERMANY

GS1-01.

Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta­analysis of 21,000 women in 16 randomised trials

敬请期待！

GS1­02.

NSABP B­47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node­positive or high­risk node­negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2­Low IBC)

敬请期待！

GS1­03. 

The comparative clinical utility of Ki67 at baseline and after 2 weeks of pre­operative aromatase inhibitor (AI) in predicting long­term outcome in early breast cancer ­ the POETIC* trial  (CRUK/07/015)

GS1-03：围术期AI治疗决定或预测早期乳腺癌的远期预后——POETIC试验（CRUK/07/015）

GS1­04. 

Copy number aberration analysis to predict response to neoadjuvant anti­HER2 therapy: results from the NeoALTTO phase III trial

GS1-04：拷贝数异常提示新辅助抗HER2治疗效果：NeoALTTOIII

GS1­05. 

Tandem duplicator phenotypes define 50% of triple negative breast cancers

GS1-05：50%的三阴性乳腺癌为串联重复表型

GS1­06. 

Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease­free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study

GS1-06早期乳腺癌患者>5年相比于2年辅助双磷酸盐治疗不能改善无病生存和总体生存：来自SUCCESS A 研究的III期数据

GS1­07. 

Sacituzumab govitecan (IMMU­132), an anti­Trop­2­SN­38 antibody­drug conjugate, as≥3rd­line therapeutic option for patients with relapsed/refractory metastatic triple­negative breast cancer (mTNBC): efficacy results

GS1-07抗Trop-2-SN-38抗体药物复合物Sacituzumab govitecan（IMMU-132）作为三线方案治疗复发/顽固转移性三阴性乳腺癌的疗效分析

GS2­01.

Discovery and characterization of an estrogen bound LncRNA in late­stage breast cancer

[GS2-01] 晚期乳腺癌中雌激素结合型LncRNA的发现及其特征

GS2­02.

 Direct regulation of estrogen receptor­α (ER) transcriptional activity by NF1

 [GS2-02]NF1直接调控ER-α的转录活性

GS2­03. 

Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER­ positive breast cancers

[GS2-03]内分泌耐药的晚期ER+乳腺癌存在高频的转录重构突变

GS2­04. 

Discussant 

敬请期待！

GS2­05. 

First­line ribociclib vs placebo with goserelin and tamoxifen or a non­steroidal aromatase inhibitor in premenopausal women with hormone receptor­positive, HER2­negative advanced breast cancer: Results from the randomized phase III MONALEESA­7 trial

敬请期待！

GS2­06. 

Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab­resistant HER2­positive metastatic breast cancer: Results from the PANACEA (IBCSG 45­13/KEYNOTE­014) study

敬请期待！

GS2­07.

MANTA ­A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor­positive advanced or metastatic breast cancer

[GS2-07] II期随机临床试验MANTA研究：氟维司群联合mTOR双重抑制剂（AZD2014）或依维莫司vs氟维司群单药治疗ER+晚期或转移性乳腺癌

Day 3: Thursday, 12/7/2017

GENERAL SESSION 3 – Hall 3

Moderator: Suleiman Massarweh, MD

Stanford University

Stanford, CA

GS3-01. 

A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of Anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial

敬请期待！

GS3-02. 

Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab

[GS3-02] 新辅助拉帕替尼+化疗+曲妥珠单抗方案的无浸润疾病生存及基因表达标记物研究：III期随机对照试验CALGB（Alliance）40601

GS3-03. 

A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn Celecoxib Trial)

[GS3-03]塞来昔布对比安慰剂辅助治疗原发性乳腺癌的III期多中心随机双盲试验（REACT）

GS3-04. 

A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

敬请期待！

GS3-05. 

Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline-cyclosphosphamide for patients with early breast cancer - GBG69

[GS3-05]前瞻性III期随机GeparSepto试验的生存分析结果

GS3-06. 

Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (IX) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)

[GS3-06] III期随机试验CALGB 4502/NCCTG N 063H(Alliance)的远期随访

GS3-07. 

Genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNA

[GS3-07]利用cfDNA分析化疗耐药的转移性三阴性乳腺癌的全基因组拷贝数

GS3-08. 

Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

[GS3-08]I-SPY2试验中pCR与无事件生存及无远处转移生存的相关性分析结果

GS4-01.

Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients

敬请期待！

GS4-02. 

Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

【2017 SABCS】[GS4-02]辅助依西美坦（E）+OFS和他莫昔芬（T）+OFS于绝经前HR+早期乳腺癌患者中的随机对照试验：TEXT和SOFT试验联合分析结果更新

GS4-03. 

Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

敬请期待！

GS4-04. 

Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200)

敬请期待！

GS4-05. 

Discussant    

敬请期待！

GS4-06. 

Cancer risks and response to targeted therapy associated with BRCA2 variants of uncertain significance

【2017 SABCS】[GS4-06]临床价值不明的BRCA2突变的致癌风险及靶向治疗敏感性    

GS4-07. 

Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer    

【2017 SABCS】[GS4-07] 依西美坦±恩杂鲁胺治疗HR+乳腺癌的随机安慰剂对照II期临床研究结果

Day 4: Friday, 12/8/2017

GENERAL SESSION 5 - Hall 3

Moderator: Seema Khan, SM MB

Northwestern University

Chicago, IL 

GS5-01. 

Appropriate margins for breast conserving surgery in patients with early stage breast cancer: A meta-analysis

【2017 SABCS】[GS5-01] 关于早期乳腺癌患者保乳手术合理切缘的meta分析

GS5-02. 

Axillary dissection vs. no axillary dissection in patients with cT1-T2cN0M0 breast cancer and only micrometastases in the sentinel node(s): Ten-year results of the IBCSG 23-01 trial 

【2017 SABCS】[GS5-02]仅伴前哨淋巴结微转移的cT1-2N0M0乳腺癌患者腋窝清扫对比无腋窝清扫的10年随访结果：IBCSG 23-01试验

GS5-03. 

Risk of arm morbidity after local therapy in young breast cancer survivors

敬请期待！

GS5-04. 

Prediction of occult invasive disease in ductal carcinoma in situ using deep learning features

【2017 SABCS】[GS5-04] 利用深度学习预测导管原位癌中的隐匿性浸润成分

GS5-05. 

Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) CALGB 40903 (Alliance)

【2017 SABCS】[GS5-05] ER+DCIS的新辅助内分泌治疗：CALGB 40903试验（Alliance）

GS5-06. 

A U.S. Food and Drug Administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy

敬请期待！   

GS5-07. 

Weight change in postmenopausal women and breast cancer risk in the Women's Health Initiative Observational study

敬请期待！   

GS5-08. 

A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS)

【2017 SABCS】[GS5-08]DCIS生物风险模型的验证：SweDICS试验20年随访结果

GS6-01. 

Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy

【2017 SABCS】[GS6-01]HR+乳腺癌患者5年内分泌治疗后晚期远处复发的临床预测模型

GS6-02. 

The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies

【2017 SABCS】[GS6-02]预测Abemaciclib获益的亚组分析：MONARCH2&3试验的联合分析

GS6-03. 

Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer

敬请期待！   

GS6-04. 

The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrine therapy in HR+/HER2- breast cancer patients from ABCSG 34

【2017 SABCS】[GS6-04]EndoPredict评分预测HR+HER2-乳腺癌患者新辅助化疗或内分泌治疗后残留肿瘤负荷

GS6-05. 

Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer

【2017 SABCS】[GS6-05]功能获得激酶库筛查发现FGFR1扩增是ER+乳腺癌对抗激素治疗和CDK4/6抑制剂耐药的机制

GS6-06. 

Identifying metastatic drivers in patient-derived xenograft models of triple negative breast cancer

【2017 SABCS】[GS6-06]发现三阴性乳腺癌人源移植瘤中的转移驱动基因

GS6-07. 

EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

敬请期待！